BioCentury | Jan 21, 2010
Distillery Techniques

Technology: Drug platforms

...B.V.'s next steps include increasing antibody yield and screening for neutralizing antibodies against other pathogens. Calmune Corp....
BioCentury | Jan 14, 2010
Tools & Techniques

Making mAbs en masse

...in the transfection and screening process is inefficient. Jay Wadia, VP of discovery research at Calmune Corp....
...N.V. partnered with Calmune to screen for antibodies against an undisclosed infectious disease target using Calmune's...
...donors and screen for antibodies against a range of other viruses. While AIMM, Humabs and Calmune...
BioCentury | Nov 9, 2009
Company News

Calmune, Crucell deal

...the resulting mAbs. Calmune is eligible for milestones and royalties. Further terms were not disclosed. Calmune Corp....
Items per page:
1 - 3 of 3
BioCentury | Jan 21, 2010
Distillery Techniques

Technology: Drug platforms

...B.V.'s next steps include increasing antibody yield and screening for neutralizing antibodies against other pathogens. Calmune Corp....
BioCentury | Jan 14, 2010
Tools & Techniques

Making mAbs en masse

...in the transfection and screening process is inefficient. Jay Wadia, VP of discovery research at Calmune Corp....
...N.V. partnered with Calmune to screen for antibodies against an undisclosed infectious disease target using Calmune's...
...donors and screen for antibodies against a range of other viruses. While AIMM, Humabs and Calmune...
BioCentury | Nov 9, 2009
Company News

Calmune, Crucell deal

...the resulting mAbs. Calmune is eligible for milestones and royalties. Further terms were not disclosed. Calmune Corp....
Items per page:
1 - 3 of 3